Media

Product rebranding as TutiviaTM

November 1, 2022
Verici Dx’s post-transplant test, Tuteva, to be rebranded as TutiviaTM Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that its post-transplant blood test focused on acute rejection, has been rebranded as TutiviaTM. TutiviaTM (formerly known as Tuteva), is a blood-based RNA signature for a risk score for acute […]
Keep Reading

Half-year report

September 7, 2022
Strong data in validation study for Tuteva™ paving the way for commercial launch
Keep Reading

Positive results for Clarava™ from blinded multi-centre clinical validation study

September 6, 2022
Data validates Clarava’s ability to identify patients likely to experience future kidney transplant rejection
Keep Reading

Result of AGM and voting results

June 28, 2022
Verici DX announces that at the Annual General Meeting
Keep Reading

Distribution of Verici Dx shares by EKF Diagnostics Holdings plc

June 20, 2022
Verici DX notes the announcement made by EKF Diagnostics Holdings PLC
Keep Reading

Investor Update

June 16, 2022
Sara Barrington, CEO, will provide a live presentation relating to positive data from the Tuteva™ clinical validation study via the Investor Meet Company platform
Keep Reading

Further data from Tuteva™ clinical validation study presented

June 14, 2022
Performance in blinded multi-centre trial establishes new industry standard in detection of acute kidney transplant rejection and paves way for US commercial launch in 2022
Keep Reading

Commercial Team Appointments

June 9, 2022
Verici Dx plc announces the senior appointments of Grant Harvey and Dr. Windy Tucci as Business Development Director and Medical Science Liaison Director
Keep Reading

Posting of Annual Report & Accounts and Notice of Annual General Meeting

May 25, 2022
Verici Dx plc confirms that the Annual Report and Accounts and the Notice of the 2022 Annual General Meeting have now been published
Keep Reading
1 2 3 7
crossmenuchevron-down